Published in N Engl J Med on March 31, 2011
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir | NCT02113631
Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients | NCT02057003
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6) | NCT01949168
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (2014) 3.95
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut (2014) 2.33
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis (2015) 2.08
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Hepatitis C. Lancet (2015) 1.95
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol (2013) 1.89
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut (2013) 1.88
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol (2012) 1.85
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci (2014) 1.63
Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. J Infect Dis (2015) 1.56
Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J (2013) 1.52
Multiplexed quantification of nucleic acids with large dynamic range using multivolume digital RT-PCR on a rotational SlipChip tested with HIV and hepatitis C viral load. J Am Chem Soc (2011) 1.51
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology (2012) 1.47
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology (2013) 1.46
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Hepatitis C virus host cell entry. Curr Opin Virol (2012) 1.41
Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection. Dig Dis Sci (2013) 1.41
Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. PLoS One (2016) 1.39
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol (2014) 1.36
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A (2013) 1.28
Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol (2011) 1.25
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology (2012) 1.24
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2014) 1.23
Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother (2013) 1.22
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother (2012) 1.21
Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc (2011) 1.20
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother (2014) 1.20
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol (2014) 1.19
Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 1.19
Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med (2012) 1.18
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One (2012) 1.17
What's fueling the biotech engine--2010 to 2011. Nat Biotechnol (2011) 1.17
The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver (2011) 1.17
Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother (2012) 1.16
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A (2012) 1.15
Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis (2013) 1.15
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Barriers to hepatitis C treatment. Liver Int (2012) 1.13
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
Treating hepatitis C - what's new? Aust Prescr (2015) 1.12
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol (2013) 1.12
Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol (2013) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther (2012) 1.11
National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis (2014) 1.10
Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther (2013) 1.09
Emerging therapies for the treatment of hepatitis C. EMBO Mol Med (2014) 1.09
Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J (2014) 1.09
Cell and tissue engineering for liver disease. Sci Transl Med (2014) 1.08
Bacterial proteolytic complexes as therapeutic targets. Nat Rev Drug Discov (2012) 1.08
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother (2011) 1.08
Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 1.08
Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol (2012) 1.08
Chronic hepatitis C: future treatment. Clin Pharmacol (2014) 1.08
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies. Therap Adv Gastroenterol (2016) 1.07
Emerging therapies for hepatitis C. Gut Liver (2014) 1.07
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther (2012) 1.07
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A (2012) 1.07
Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother (2011) 1.06
Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol (2012) 1.06
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One (2012) 1.05
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology (2012) 1.04
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol (2013) 1.02
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis (2000) 6.54
Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat (1999) 6.42
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology (2010) 2.44
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet (2001) 2.40
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 7.91
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Liver biopsy. Hepatology (2009) 7.61
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology (2007) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 2.66
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med (2010) 2.44
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43